The mechanisms of serum-treated zymosan (STZ)-induced oxidative metabolism by human eosinophils and the effects of IL-5 priming.
BACKGROUND
The aim of this work was to study the mechanisms of action of IL-5 on the subsequent stimulation of the oxidative metabolism of blood eosinophils by serum-treated zymosan (STZ), in terms of signal transduction characteristics, and by comparing the response of cells from healthy and allergic subjects during environmental exposure to birch pollen.


METHODS
Eosinophils from healthy controls and allergic patients were purified to over 95% by Percoll gradients and the MACS system. Oxidative metabolism was measured by a lucigenin-enhanced chemiluminescence (CL) assay. Eosinophils were primed with IL-5 and subsequently stimulated with STZ. The signal transduction mechanisms of IL-5 priming were studied with the MEK inhibitor PD 98059,the PkC inhibitors staurosporine and Ro 318220, and the PI3 kinase inhibitor wortmannin.


RESULTS
IL-5 increased the maximum radical production (P=0.0079) and reduced the t(1/2) rise (0.000018) of the CL reactions. The t(1/2) rise was PkC dependent and MEK independent, while the maximum radical production was PkC, MEK, and PI3 kinase dependent. During the pollen season, IL-5 reduced the total STZ-induced CL response in the patients' cells (P=0.016), but not in the control cells, whereas it primed the response to STZ of both cell populations in terms of the t(1/2) rise (P=0.012 and 0.00066, respectively).


CONCLUSIONS
STZ-induced oxidative metabolism consists of different stages. The initial stage (t(1/2) rises of the curves) is PkC dependent and MEK independent, while the end stage (maximum radical production) is PkC, MEK, and PI3 kinase dependent. IL-5 shortened the initial stage, and increased the end stage. During allergen exposure, however, the end stage was reduced by IL-5. This could be due to increased amounts of hypodense eosinophils and/or some abnormality in cell responses.
Woschnagg
C
C
Department of Medical Sciences, Clinical Chemistry, University Hospital, Uppsala, Sweden.
Garcia
R C
RC
Venge
P
P
D002352:Carrier Proteins / Q000187:drug effects / Q000378:metabolism; D004781:Environmental Exposure / Q000009:adverse effects; D004791:Enzyme Inhibitors / Q000378:metabolism; D004804:Eosinophils / Q000187:drug effects* / Q000378:metabolism*; D005609:Free Radicals / Q000097:blood; D006801:Humans; D006967:Hypersensitivity / Q000097:blood*; D015848:Interleukin-5 / Q000494:pharmacology*; D047908:Intracellular Signaling Peptides and Proteins; D008163:Luminescent Measurements; D010084:Oxidation-Reduction / Q000187:drug effects*; D011058:Pollen / Q000009:adverse effects; D019311:Staurosporine / Q000378:metabolism; D015054:Zymosan / Q000097:blood* / Q000627:therapeutic use*
D002352:Carrier Proteins; D004791:Enzyme Inhibitors; D005609:Free Radicals; D015848:Interleukin-5; D047908:Intracellular Signaling Peptides and Proteins; C015482:protein kinase modulator; D015054:Zymosan; D019311:Staurosporine